|Triple-negative breast cancer: clinical features and patterns of recurrence|
R Dent, M Trudeau, KI Pritchard, WM Hanna, HK Kahn, CA Sawka, ...
Clinical cancer research 13 (15), 4429-4434, 2007
|Pathologic Complete Response Rates in Young Women With BRCA1-Positive Breast Cancers After Neoadjuvant Chemotherapy|
T Byrski, J Gronwald, T Huzarski, E Grzybowska, M Budryk, M Stawicka, ...
Journal of Clinical Oncology 28 (3), 375-379, 2010
|Pattern of metastatic spread in triple-negative breast cancer|
R Dent, WM Hanna, M Trudeau, E Rawlinson, P Sun, SA Narod
Breast cancer research and treatment 115 (2), 423-428, 2009
|Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial|
D Cameron, J Brown, R Dent, C Jackisch, J Mackey, X Pivot, GG Steger, ...
The lancet oncology 14 (10), 933-942, 2013
|Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients|
T Byrski, T Huzarski, R Dent, J Gronwald, D Zuziak, C Cybulski, J Kladny, ...
Breast cancer research and treatment 115 (2), 359-363, 2009
|Survival outcomes for patients with metastatic triple-negative breast cancer: implications for clinical practice and trial design|
F Kassam, K Enright, R Dent, G Dranitsaris, J Myers, C Flynn, M Fralick, ...
Clinical breast cancer 9 (1), 29-33, 2009
|Pathologic complete response to neoadjuvant cisplatin in BRCA1-positive breast cancer patients|
T Byrski, T Huzarski, R Dent, E Marczyk, M Jasiówka, J Gronwald, ...
Breast cancer research and treatment 147 (2), 401-405, 2014
|Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind …|
SB Kim, R Dent, SA Im, M Espié, S Blau, AR Tan, SJ Isakoff, M Oliveira, ...
The Lancet Oncology 18 (10), 1360-1372, 2017
|Results of a phase II open-label, non-randomized trial of cisplatin chemotherapy in patients with BRCA1-positive metastatic breast cancer|
T Byrski, R Dent, P Blecharz, M Foszczynska-Kloda, J Gronwald, ...
Breast cancer research 14 (4), R110, 2012
|Targeting triple-negative breast cancer: optimising therapeutic outcomes|
K Gelmon, R Dent, JR Mackey, K Laing, D McLeod, S Verma
Annals of oncology 23 (9), 2223-2234, 2012
|ESO-ESMO 3rd international consensus guidelines for breast cancer in young women (BCY3)|
S Paluch-Shimon, O Pagani, AH Partridge, O Abulkhair, MJ Cardoso, ...
The Breast 35, 203-217, 2017
|Including older people in clinical research|
MET McMurdo, MD Witham, ND Gillespie
Bmj 331 (7524), 1036-1037, 2005
|Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first-or second-line treatment of patients with metastatic triple-negative breast cancer|
RA Dent, GJ Lindeman, M Clemons, H Wildiers, A Chan, NJ McCarthy, ...
Breast cancer research 15 (5), R88, 2013
|Poly (ADP-Ribose) polymerase inhibition:“targeted” therapy for triple-negative breast cancer|
CK Anders, EP Winer, JM Ford, R Dent, DP Silver, GW Sledge, LA Carey
Clinical Cancer Research 16 (19), 4702-4710, 2010
|Functional imaging using diffuse optical spectroscopy of neoadjuvant chemotherapy response in women with locally advanced breast cancer|
H Soliman, A Gunasekara, M Rycroft, J Zubovits, R Dent, J Spayne, ...
Clinical Cancer Research 16 (9), 2605-2614, 2010
|Association of proinflammatory cytokines and chemotherapy-associated cognitive impairment in breast cancer patients: a multi-centered, prospective, cohort study|
YT Cheung, T Ng, M Shwe, HK Ho, KM Foo, MT Cham, JA Lee, G Fan, ...
Annals of Oncology 26 (7), 1446-1451, 2015
|Tamoxifen metabolism predicts drug concentrations and outcome in premenopausal patients with early breast cancer|
P Saladores, T Mürdter, D Eccles, B Chowbay, NK Zgheib, S Winter, ...
The pharmacogenomics journal 15 (1), 84-94, 2015
|Patterns of recurrence in the basal and non-basal subtypes of triple-negative breast cancers|
S Nofech-Mozes, M Trudeau, HK Kahn, R Dent, E Rawlinson, P Sun, ...
Breast cancer research and treatment 118 (1), 131, 2009
|Pembrolizumab for early triple-negative breast cancer|
P Schmid, J Cortes, L Pusztai, H McArthur, S Kümmel, J Bergh, C Denkert, ...
New England Journal of Medicine 382 (9), 810-821, 2020
|Quantitative ultrasound evaluation of tumor cell death response in locally advanced breast cancer patients receiving chemotherapy|
A Sadeghi-Naini, N Papanicolau, O Falou, J Zubovits, R Dent, S Verma, ...
Clinical Cancer Research 19 (8), 2163-2174, 2013